United States securities and exchange commission logo





                             December 7, 2020

       Chris Downs
       Chief Financial Officer
       CNS Pharmaceuticals, Inc.
       2100 West Loop South, Suite 900
       Houston, TX 77027

                                                        Re: CNS
Pharmaceuticals, Inc.
                                                            Draft Registration
Statement on Form S-1
                                                            Submitted November
30, 2020
                                                            CIK No. 0001729427

       Dear Mr. Downs:

                                                        This is to advise you
that we do not intend to review your registration statement.

               We request that you publicly file your registration statement no
later than 48 hours prior
       to the requested effective date and time. Please refer to Rules 460 and
461 regarding requests for
       acceleration. We remind you that the company and its management are
responsible for the
       accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
       absence of action by the staff.

                                                        Please contact Laura
Crotty at 202-551-7614 with any questions.




                             Sincerely,


                             Division of Corporation Finance

                             Office of Life Sciences
       cc:                                              Cavas S. Pavri